anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

21 Before After

Loop collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 3,571
Current window 2,281-2,310
Pages 120
Rows per page 30
Loop: 21 Before Afterclear collectionreset all
18 30 60

Loop

2,281-2,310 of 3,571

filter-aware
04
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
05
The slide uses a timeline-based process diagram to explain the clinical trial structure.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
06
Mentions specific statistical models: PCA, MMRM, and mixed stepwise regression.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
07
The slide outlines the primary endpoint (Clinical Response) and a secondary/supporting metric (piecewise slope) for ALS clinical trials.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
08
The slide details the specific biomarkers used in the study and the exclusion criteria based on missing data.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
09
The chart displays the first principal component for each pathway over 20 weeks, comparing NurOwn and Placebo groups.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The slide uses a consistent color scheme (blue for NurOwn, red for Placebo) and indicates statistical significance with asterisks.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
15
Shows strategic pivot of Credit Suisse capital allocation.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
16
The chart shows the bridge from the 3Q22 baseline to the 2025 target, accounting for capital raises, divestments, generation, and usage.Credit Suisse | Investor Event Presentation Deck | 43 slides · Credit Suisse
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
10
The chart illustrates the reconciliation of operating expenses between two periods.Credit Suisse | Results Presentation Deck | 26 slides · Credit Suisse
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
07
Uses a chevron-style transition to show the shift from investment to optimization.Hydrafacial | Investor Presentation Deck | 9 slides · BeautyHealth
Conference presentation Investor relations Beat · The BreakthroughLoop · Before After1 hit
08
The chart shows a breakdown of market segments (Hospitality, Medical, Spa) and a stacked bar chart of system sales (New vs Trade-Ups).Hydrafacial | Investor Presentation Deck | 9 slides · BeautyHealth
Conference presentation Investor relations Beat · The BreakthroughLoop · Before After1 hit
09
The chart illustrates a steady upward trend in system utilization over 10 quarters.Hydrafacial | Investor Presentation Deck | 9 slides · BeautyHealth
Conference presentation Investor relations Beat · The BreakthroughLoop · Before After1 hit
06
The slide uses a before-after framework to contrast the focus areas of two clinical trial phases, followed by a numbered list of specific improvements.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
07
The slide uses a process-flow layout to show progression from Phase 1a to 1b to final takeaways.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
08
Includes footnotes defining abbreviations and trial parameters.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
09
Data cut-off date is 06-Sept-2022. Includes footnotes regarding patient outcomes and definitions.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
Data cut-off 06-Sept-2022. Footnotes define ORR and cORR criteria.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
11
The slide uses waterfall charts to visualize clinical trial efficacy across various solid tumor types.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
12
Clinical trial data visualization using spider plots (spaghetti plots) to track individual patient tumor burden changes.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
13
Includes longitudinal persistence data, peak frequency comparison, and tumor infiltration correlation with clinical response (PD/SD vs PR/cPR).Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
14
The chart uses a Mann-Whitney U test to compare the two groups (p=0.076).Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
15
Immatics | Results Presentation Deck | 25 slidesImmatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
23
Data presented as Kaplan-Meier survival curves and tumor growth kinetics/bar charts.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
25
The table uses checkmarks, crosses, and question marks to indicate performance/capability across different cell types.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
26
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
27
The slide presents clinical efficacy metrics (ORR, SD, mOS) and safety profile for iNKT cell therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
15
Uses a before-after framework to show portfolio evolution from a concentrated local model to a diversified national model.Western Alliance Bancorporation | Results Presentation Deck | 21 slides · Western Alliance Bancorporation
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit